Net margin is calculated as Net Income divided by its Revenue. Bod Science's Net Income for the
six
months ended in Jun. 2025 was A$0.28 Mil. Bod Science's Revenue for the
six
months ended in Jun. 2025 was A$0.88 Mil. Therefore, Bod Science's net margin for the quarter that ended in Jun. 2025 was 31.11%.
The historical rank and industry rank for Bod Science's Net Margin % or its related term are showing as below:
ASX:BOD'
s Net Margin % Range Over the Past 10 Years
Min: -929.76 Med: -430.48 Max: 17.44
Current: 17.44
ASX:BOD's Net Margin % is not ranked
in the Drug Manufacturers industry.
Industry Median: 5.56
vs ASX:BOD: 17.44
Bod Science (ASX:BOD) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Bod Science Net Margin % Related Terms
Bod Science Net Margin % Historical Data
* Premium members only.
The historical data trend for Bod Science's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bod Science's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bod Science Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bod Science's Net Margin % distribution charts can be found below:
* The bar in red indicates where Bod Science's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bod Science (ASX:BOD) has a Net Margin % of 31.11% as of Jun. 2025. Net margin is the ratio of total net income to net sales. View historical data on Bod Science and its competitors.
Is Bod Science's Net Margin % too high?
Bod Science's current Net Margin % is 31.11%. The Drug Manufacturers industry median Net Margin % is 5.56. Bod Science's value of 31.11% is 459.5% above this industry median. Overall, Bod Science has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Bod Science's Net Margin % compare to ZTS?
Bod Science's Net Margin % of 31.11% can be compared against companies in the Drug Manufacturers industry. The industry median Net Margin % is 5.56. Bod Science's value of 31.11% is 459.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bod Science's current Net Margin % of 31.11% is 459.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Bod Science and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bod Science's current Net Margin % is 31.11%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bod Science stock overvalued right now?
Bod Science (ASX:BOD) has a current Net Margin % of 31.11%. The stock's GF Value™ is A$0.04, compared to a current price of A$0.02 — trading 40% below its estimated fair value. The current Net Margin % is 31.11% and 459.5% above the Drug Manufacturers industry median of 5.56. Bod Science's overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Bod Science (ASX:BOD), the current Net Margin % is 31.11% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bod Science (ASX:BOD) Overvalued in 2026?
Based on GuruFocus' analysis, Bod Science stock appears to be undervalued.
The current stock price of A$0.02 is trading 40% below its estimated GF Value™ of A$0.04.
Key valuation signals for ASX:BOD:
Net Margin %: 31.11%
GF Value™: A$0.04 vs. price of A$0.02 (40% below fair value)
Industry Position: 459.5% above the Drug Manufacturers median
No single metric tells the full story. See the ASX:BOD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bod Science Ltd is a healthcare company combining the power of nature and science to deliver cannabis-derived health and skincare products, designed to improve lives and transform the medicinal cannabis, CBD, and hemp market. The firm is focused on cannabis drug development and products. The company is focused on progressing Research and Development and a defined clinical trial pathway to commercialize and deliver premium, scientifically trusted products for the consumer and medical markets. It earned it profits and sales revenue from Australia even though have segment in UK, Europe and USA.
12GF Score
Get the complete analysis for ASX:BOD
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BOD has been successfully added to your 
